PHG Quote, Financials, Valuation and Earnings

argenx SE has a net margin of -24.14% compared to Koninklijke Philips NV's net margin of 15.95%. Koninklijke Philips NV's return on equity of -- beat argenx SE's return on equity of -6.01%.

Koninklijke Philips NV has a consensus price target of $35.17, signalling upside risk potential of 35.01%. On the other hand argenx SE has an analysts' consensus of $701.57 which suggests that it could grow by 9.53%. Given that Koninklijke Philips NV has higher upside potential than argenx SE, analysts believe Koninklijke Philips NV is more attractive than argenx SE.

Koninklijke Philips NV has a beta of 0.762, which suggesting that the stock is 23.8% less volatile than S&P 500. In comparison argenx SE has a beta of 0.587, suggesting its less volatile than the S&P 500 by 41.304%.

Koninklijke Philips NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. argenx SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Koninklijke Philips NV pays -0.43% of its earnings as a dividend. argenx SE pays out -- of its earnings as a dividend.

Koninklijke Philips NV quarterly revenues are $4.5B, which are larger than argenx SE quarterly revenues of $573.2M. Koninklijke Philips NV's net income of -$1.1B is lower than argenx SE's net income of $91.4M. Notably, Koninklijke Philips NV's price-to-earnings ratio is -- while argenx SE's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Koninklijke Philips NV is 1.31x versus 21.00x for argenx SE. Usually stocks with elevated PS ratios are considered overvalued.

Autolus Therapeutics PLC has a net margin of -24.14% compared to Koninklijke Philips NV's net margin of -522.15%. Koninklijke Philips NV's return on equity of -- beat Autolus Therapeutics PLC's return on equity of -80.74%.

Koninklijke Philips NV has a consensus price target of $35.17, signalling upside risk potential of 35.01%. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $10.45 which suggests that it could grow by 365.09%. Given that Autolus Therapeutics PLC has higher upside potential than Koninklijke Philips NV, analysts believe Autolus Therapeutics PLC is more attractive than Koninklijke Philips NV.

Koninklijke Philips NV has a beta of 0.762, which suggesting that the stock is 23.8% less volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 2.049, suggesting its more volatile than the S&P 500 by 104.921%.

Koninklijke Philips NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Koninklijke Philips NV pays -0.43% of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.

Koninklijke Philips NV quarterly revenues are $4.5B, which are larger than Autolus Therapeutics PLC quarterly revenues of $10.1M. Koninklijke Philips NV's net income of -$1.1B is lower than Autolus Therapeutics PLC's net income of -$82.1M. Notably, Koninklijke Philips NV's price-to-earnings ratio is -- while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Koninklijke Philips NV is 1.31x versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of -24.14% compared to Koninklijke Philips NV's net margin of --. Koninklijke Philips NV's return on equity of -- beat DBV Technologies SA's return on equity of --.

Koninklijke Philips NV has a consensus price target of $35.17, signalling upside risk potential of 35.01%. On the other hand DBV Technologies SA has an analysts' consensus of $21.70 which suggests that it could grow by 385.26%. Given that DBV Technologies SA has higher upside potential than Koninklijke Philips NV, analysts believe DBV Technologies SA is more attractive than Koninklijke Philips NV.

Koninklijke Philips NV has a beta of 0.762, which suggesting that the stock is 23.8% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of 0.640, suggesting its less volatile than the S&P 500 by 36.023%.

Koninklijke Philips NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Koninklijke Philips NV pays -0.43% of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Koninklijke Philips NV quarterly revenues are $4.5B, which are larger than DBV Technologies SA quarterly revenues of --. Koninklijke Philips NV's net income of -$1.1B is lower than DBV Technologies SA's net income of -$30.4M. Notably, Koninklijke Philips NV's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Koninklijke Philips NV is 1.31x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Trinity Biotech PLC has a net margin of -24.14% compared to Koninklijke Philips NV's net margin of -31.41%. Koninklijke Philips NV's return on equity of -- beat Trinity Biotech PLC's return on equity of --.

Koninklijke Philips NV has a consensus price target of $35.17, signalling upside risk potential of 35.01%. On the other hand Trinity Biotech PLC has an analysts' consensus of -- which suggests that it could grow by 1715.98%. Given that Trinity Biotech PLC has higher upside potential than Koninklijke Philips NV, analysts believe Trinity Biotech PLC is more attractive than Koninklijke Philips NV.

Koninklijke Philips NV has a beta of 0.762, which suggesting that the stock is 23.8% less volatile than S&P 500. In comparison Trinity Biotech PLC has a beta of 1.006, suggesting its more volatile than the S&P 500 by 0.60500000000001%.

Koninklijke Philips NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trinity Biotech PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Koninklijke Philips NV pays -0.43% of its earnings as a dividend. Trinity Biotech PLC pays out -- of its earnings as a dividend.

Koninklijke Philips NV quarterly revenues are $4.5B, which are larger than Trinity Biotech PLC quarterly revenues of $15.2M. Koninklijke Philips NV's net income of -$1.1B is lower than Trinity Biotech PLC's net income of -$4.8M. Notably, Koninklijke Philips NV's price-to-earnings ratio is -- while Trinity Biotech PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Koninklijke Philips NV is 1.31x versus 0.15x for Trinity Biotech PLC. Usually stocks with elevated PS ratios are considered overvalued.